Iambic Therapeutics is a biotechnology company that is working on the therapeutics with its AI-driven drug-discovery platform. Their algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week.
Iambic Therapeutics’ pipeline of programs includes programs focusing on cryptic pockets, allostery, and protein-protein interactions, spanning multiple therapeutic areas. Some of the core products include:
- HER2: 1000x selectivity and brain penetrance to unlock the therapeutic potential of the target for metastatic disease with IND submission in 2023.
- CDK2/4: First-in-class CDK2/4 profile to address cyclin D and cyclin E driven cancers while avoiding off-target dose-limiting toxicities.
- Iambic Therapeutics has secured $100M in Series B funding as of October 3, 2023
- The company has raised a total of $150M in funding over 2 rounds.
AI-driven drug-discovery platform.